These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

490 related items for PubMed ID: 21549152

  • 1. Effect of telbivudine therapy on the cellular immune response in chronic hepatitis B.
    Chen Y, Li X, Ye B, Yang X, Wu W, Chen B, Pan X, Cao H, Li L.
    Antiviral Res; 2011 Jul; 91(1):23-31. PubMed ID: 21549152
    [Abstract] [Full Text] [Related]

  • 2. Programmed death 1 expression during antiviral treatment of chronic hepatitis B: Impact of hepatitis B e-antigen seroconversion.
    Evans A, Riva A, Cooksley H, Phillips S, Puranik S, Nathwani A, Brett S, Chokshi S, Naoumov NV.
    Hepatology; 2008 Sep; 48(3):759-69. PubMed ID: 18697210
    [Abstract] [Full Text] [Related]

  • 3. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B.
    Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, Heathcote EJ, Manns M, Bzowej N, Niu J, Han SH, Hwang SG, Cakaloglu Y, Tong MJ, Papatheodoridis G, Chen Y, Brown NA, Albanis E, Galil K, Naoumov NV, GLOBE Study Group.
    Gastroenterology; 2009 Feb; 136(2):486-95. PubMed ID: 19027013
    [Abstract] [Full Text] [Related]

  • 4. Telbivudine versus lamivudine in patients with chronic hepatitis B.
    Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, Chen Y, Heathcote EJ, Rasenack J, Bzowej N, Naoumov NV, Di Bisceglie AM, Zeuzem S, Moon YM, Goodman Z, Chao G, Constance BF, Brown NA, Globe Study Group.
    N Engl J Med; 2007 Dec 20; 357(25):2576-88. PubMed ID: 18094378
    [Abstract] [Full Text] [Related]

  • 5. A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients.
    Zheng MH, Shi KQ, Dai ZJ, Ye C, Chen YP.
    Clin Ther; 2010 Apr 20; 32(4):649-58. PubMed ID: 20435234
    [Abstract] [Full Text] [Related]

  • 6. Hepatitis B virus-specific T-cell proliferation and cytokine secretion in chronic hepatitis B e antibody-positive patients treated with ribavirin and interferon alpha.
    Rico MA, Quiroga JA, Subirá D, Castañón S, Esteban JM, Pardo M, Carreño V.
    Hepatology; 2001 Jan 20; 33(1):295-300. PubMed ID: 11124848
    [Abstract] [Full Text] [Related]

  • 7. High serum IL-21 levels after 12 weeks of antiviral therapy predict HBeAg seroconversion in chronic hepatitis B.
    Ma SW, Huang X, Li YY, Tang LB, Sun XF, Jiang XT, Zhang YX, Sun J, Liu ZH, Abbott WG, Dong YH, Naoumov NV, Hou JL.
    J Hepatol; 2012 Apr 20; 56(4):775-81. PubMed ID: 22173154
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B.
    Gane EJ, Wang Y, Liaw YF, Hou J, Thongsawat S, Wan M, Moon YM, Jia J, Chao YC, Niu J, Leung N, Samuel D, Hsu CW, Bao W, Lopez P, Avila C.
    Liver Int; 2011 May 20; 31(5):676-84. PubMed ID: 21457439
    [Abstract] [Full Text] [Related]

  • 9. On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients.
    Cai W, Xie Q, An B, Wang H, Zhou X, Zhao G, Guo Q, Gu R, Bao S.
    J Clin Virol; 2010 May 20; 48(1):22-6. PubMed ID: 20233672
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection.
    Han GR, Cao MK, Zhao W, Jiang HX, Wang CM, Bai SF, Yue X, Wang GJ, Tang X, Fang ZX.
    J Hepatol; 2011 Dec 20; 55(6):1215-21. PubMed ID: 21703206
    [Abstract] [Full Text] [Related]

  • 12. A comparison of telbivudine and entecavir for chronic hepatitis B in real-world clinical practice.
    Tsai MC, Lee CM, Chiu KW, Hung CH, Tung WC, Chen CH, Tseng PL, Chang KC, Wang JH, Lu SN, Yen YH, Hu TH.
    J Antimicrob Chemother; 2012 Mar 20; 67(3):696-9. PubMed ID: 22174039
    [Abstract] [Full Text] [Related]

  • 13. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial.
    Hou J, Yin YK, Xu D, Tan D, Niu J, Zhou X, Wang Y, Zhu L, He Y, Ren H, Wan M, Chen C, Wu S, Chen Y, Xu J, Wang Q, Wei L, Chao G, Constance BF, Harb G, Brown NA, Jia J.
    Hepatology; 2008 Feb 20; 47(2):447-54. PubMed ID: 18080339
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Treatment with telbivudine positively regulates antiviral immune profiles in Chinese patients with chronic hepatitis B.
    Ma L, Cai YJ, Yu L, Feng JY, Wang J, Li C, Niu JQ, Jiang YF.
    Antimicrob Agents Chemother; 2013 Mar 20; 57(3):1304-11. PubMed ID: 23274669
    [Abstract] [Full Text] [Related]

  • 19. [Factors associated with response to lamivudine: retrospective study of 233 patients with chronic hepatitis B].
    Zhou HJ, Li SG, Wen FY, Yang XY, Wu JL, Tan B, Fu J.
    Zhonghua Gan Zang Bing Za Zhi; 2009 Aug 20; 17(8):564-8. PubMed ID: 19719911
    [Abstract] [Full Text] [Related]

  • 20. Telbivudine for the management of chronic hepatitis B virus infection.
    Matthews SJ.
    Clin Ther; 2007 Dec 20; 29(12):2635-53. PubMed ID: 18201580
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.